Market Research Report

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives
cover Published by GBI Research
Published Product code 252729
Content info Pages: 110
Price

Introduction

Executive Summary

'Considerable Scope for Improvement' in Antidepressants Market, Says Report

Further research into the disease etiology of a number of mental health disorders would open up considerable scope for improvement in the development of antidepressants, says a new report by GBI Research.

The report* states that the global antidepressants market for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) - estimated at $11.9 billion in 2011 - is forecast to generate $13.4 billion by 2018. Antidepressants are among the top three most prescribed classes of drugs in the US, along with cholesterol-lowering drugs and painkillers.

The report states that Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed classes of antidepressants, but many patients fail to respond adequately to them, while a significant number of patients also discontinue therapy due to negative and unwanted side effects.

Latency is also a factor in drug compliance, as the positive effects of antidepressants may only be seen after around six weeks, leading to more instances of treatment discontinuance due to frustration and lost confidence in the drug. The report estimates that around 25% of patients will stop taking their prescribed medication within the first four weeks of treatment.

The pharmaceutical industry has so far struggled to improve on current antidepressants, partly due to inadequate understanding and the difficulty of conducting clinical trials, according to GBI Research analysis. A notably high placebo effect, and a lack of objective assessment criteria and financing all represent drawbacks for scientific study into antidepressant therapeutics.

Without major breakthroughs in scientific understanding, development activity in this therapeutic area will be restricted. However, this does leave considerable scope for improvement over the current treatment options if understanding of the disease etiology improves.

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

This report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). It provides the sales, treatment usage patterns for the global antidepressant market in addition to the individual indication markets. It also provides the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan, and gives insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Abstract

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives", which provides insights into the antidepressants market until 2018. The report is built using data sourced from our proprietary databases and primary and secondary research, in addition to analysis from our in-house specialized team of experts. The report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). The report provides the sales for the global antidepressant market in addition to the individual indication markets. It also examines the global antidepressant market treatment usage patterns, in addition to the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan. The report also includes insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.

GBI Research analysis shows that the overall global antidepressant market for the four indications, (MDD, OCD, GAD and PD) was valued at $11.9 billion in 2011, growing from $10.5 billion in 2004 and indicating a Compounded Annual Growth Rate (CAGR) of 1.7%. The market is forecast to reach revenues of approximately $13.4 billion by 2018 for the above mentioned four major indications, increasing at a CAGR of 1.8%. Overall the number of prescriptions for antidepressant has risen, but this has been offset by a number of patent expiries and high generic entry. Drugs currently in development have taken on a new multi-targeted approach, combining targets known to be beneficial for the treatment of MDD, OCD, GAD and PD. The future of the antidepressant market is reliant on the positive safety profiles of drugs in the pipeline, with no disease-modifying therapies expected to enter the market in the near future.

Scope

  • The report analyzes the treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global antidepressant market for MDD, OCD, GAD and PD.
  • Data and analysis on the antidepressant market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the antidepressant market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns (diseased population, diagnosis population and prescription population).
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global antidepressant market including top company benchmarking. The key companies studied in this report are Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Forest laboratories and Lundbeck.
  • Key M&A activities and licensing agreements that took place between 2009 and 2012 in the antidepressants therapeutics market.

Reasons to buy

  • Align their product portfolio to markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and the market potential of each indication.
  • Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

TOC

1 Table of Contents

1 Table of Contents 6

  • 1.1 List of Tables 9
  • 1.2 List of Figures 10

2 Antidepressants Market to 2018 - Introduction 12

3 Market Overview 13

  • 3.1 Introduction 13
  • 3.2 Classification of Antidepressants 14
    • 3.2.1 Selective Serotonin Reuptake Inhibitors 15
    • 3.2.2 Serotonin-Norepinephrine Reuptake Inhibitors 15
    • 3.2.3 Noradrenergic and Specific Serotonergic Antidepressants 15
    • 3.2.4 Norepinephrine Reuptake Inhibitors 16
    • 3.2.5 Norepinephrine-Dopamine Reuptake Inhibitors 16
    • 3.2.6 Norepinephrine-Dopamine Disinhibitors 16
    • 3.2.7 Serotonin Antagonist and Reuptake Inhibitors 16
    • 3.2.8 Tricyclic Antidepressants 16
    • 3.2.9 Tetracyclic Antidepressants 17
    • 3.2.10 Monoamine Oxidase Inhibitors 17
    • 3.2.11 Others 18
  • 3.3 Adverse Effects 18
  • 3.4 Major Marketed Products in the Antidepressants Therapy Area 18
  • 3.5 Future Developments 20
  • 3.6 Revenue 21
  • 3.7 Annual Cost of Therapy 23
  • 3.8 Treatment Usage Patterns 24
    • 3.8.1 Diseased Population 25
    • 3.8.2 Diagnosed Population 25
    • 3.8.3 Prescription Population 25
  • 3.9 Drivers and Restraints of the Antidepressants Market 26
    • 3.9.1 Drivers 26
    • 3.9.2 Restraints 27

4 Therapeutic Landscape 28

  • 4.1 Antidepressants Market for Major Depressive Disorder 28
    • 4.1.1 Introduction 28
    • 4.1.2 Revenue and Forecasts 30
    • 4.1.3 Annual Cost of Therapy 31
    • 4.1.4 Treatment Usage Patterns 32
    • 4.1.5 Geographical Segmentation 33
  • 4.2 Drivers and Restraints for the Antidepressants Market for Major Depressive Disorder 35
    • 4.2.1 Drivers 35
    • 4.2.2 Restraints 35
  • 4.3 Antidepressants Market for Obsessive-Compulsive Disorder 37
    • 4.3.1 Introduction 37
    • 4.3.2 Revenue and Forecasts 39
    • 4.3.3 Annual Cost of Therapy 40
    • 4.3.4 Treatment Usage Patterns 41
    • 4.3.5 Geographical Segmentation 42
  • 4.4 Drivers and Restraints for the Antidepressants Market for Obsessive-Compulsive Disorder 44
    • 4.4.1 Drivers 44
    • 4.4.2 Restraints 44
  • 4.5 Antidepressants Market for Generalized Anxiety Disorder 45
    • 4.5.1 Introduction 45
    • 4.5.2 Revenue and Forecasts 46
    • 4.5.3 Annual Cost of Therapy 48
    • 4.5.4 Treatment Usage Patterns 49
    • 4.5.5 Geographical Segmentation 51
  • 4.6 Drivers and Restraints for the Antidepressants Market for Generalized Anxiety Disorder 54
    • 4.6.1 Drivers 54
    • 4.6.2 Restraints 54
  • 4.7 Antidepressants Market for Panic Disorder 55
    • 4.7.1 Introduction 55
    • 4.7.2 Revenue and Forecasts 58
    • 4.7.3 Annual Cost of Therapy 59
    • 4.7.4 Treatment Usage Patterns 60
    • 4.7.5 Geographical Segmentation 62
  • 4.8 Drivers and Restraints for the Antidepressants Market for Panic Disorder 64
    • 4.8.1 Drivers 64
    • 4.8.2 Restraints 64

5 Geographical Landscape 66

  • 5.1 The US 67
    • 5.1.1 Revenue and Forecasts 67
    • 5.1.2 Annual Cost of Therapy 69
    • 5.1.3 Treatment Usage Patterns 70
  • 5.2 EU5 72
    • 5.2.1 Revenue and Forecasts 72
    • 5.2.2 Annual Cost of Therapy 73
    • 5.2.3 Treatment Usage Patterns 74
  • 5.3 Japan 75
    • 5.3.1 Revenue and Forecasts 75
    • 5.3.2 Annual Cost of Therapy 76
    • 5.3.3 Treatment Usage Patterns 77

6 Pipeline Analysis 79

  • 6.1 Introduction 79
  • 6.2 Summary of the Current Antidepressants R&D Pipeline 79
  • 6.3 Profiles of Key Late-Stage Drugs in the Antidepressants Market 82
    • 6.3.1 Vortioxetine (Lu AA21004) 82
    • 6.3.2 F-2695 (levomilnacipran) 83
    • 6.3.3 LY-2216684 (edivoxetine) 84
    • 6.3.4 OPC-34712 84
    • 6.3.5 EB-1010/Amitifadine 85
    • 6.3.6 PNB01 86

7 Competitive Landscape 87

  • 7.1 Competitive Profiling 87
    • 7.1.1 H. Lundbeck 87
    • 7.1.2 AstraZeneca 88
    • 7.1.3 Eli Lilly and Company 89
    • 7.1.4 Forest Laboratories 90
    • 7.1.5 Pfizer Inc. 92
    • 7.1.6 GlaxoSmithKline 93
    • 7.1.7 Bristol-Myers Squibb Company 94

8 Strategic Consolidations 96

  • 8.1 Merger and Acquisition Deals 96
    • 8.1.1 Paladin Labs Completes Acquisition of Labopharm 96
    • 8.1.2 High River Acquires 6.5% Stake in Forest Laboratories 96
    • 8.1.3 Forest Laboratories Completes Acquisition of Clinical Data 96
    • 8.1.4 Azur Pharma Completes Merger with Jazz Pharmaceuticals in All Stock Transaction 97
    • 8.1.5 Nuvo Research Acquires ZARS Pharma 97
    • 8.1.6 Sun Pharmaceutical Acquires Remaining 24% Stake of Caraco Pharmaceutical 98
  • 8.2 Licensing Agreements 98
    • 8.2.1 Labopharm Enters into Licensing Agreement with Angelini Group for OLEPTRO 98
    • 8.2.2 Omeros Expands Licensing Agreement with Daiichi Sankyo 98
    • 8.2.3 Jazz Pharmaceuticals Enters into Sub-Licensing Agreement with Anchen 98
    • 8.2.4 AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept 99
    • 8.2.5 Indevus Pharmaceuticals Enters into Licensing Agreement with Teva Pharmaceutical 99
    • 8.2.6 Impax Laboratories Enters into Licensing Agreement with Wyeth 99
    • 8.2.7 Mylan Enters into Licensing Agreement with GlaxoSmithKline 99
    • 8.2.8 Tikvah Therapeutics Signs Licensing Agreement with Therapade Technologies 99
    • 8.2.9 GlaxoSmithKline Signs an Agreement with Fabre-Kramer Pharmaceuticals 100
    • 8.2.10 Jazz Pharmaceuticals Enters into Licensing Agreement with Solvay 100
    • 8.2.11 Targacept Enters into Licensing Agreement with Yale University 100
  • 8.3 Co-Development Deals 100
    • 8.3.1 Lundbeck Enters into Co-Development Agreement with Otsuka Pharmaceutical 100
    • 8.3.2 Eli Lilly Terminates Co-Development Agreement with Boehringer Ingelheim 101
    • 8.3.3 Lundbeck Enters into Co-Development Agreement with Takeda 101

9 Appendix 102

  • 9.1 Market Definitions 102
  • 9.2 Abbreviations 102
  • 9.3 Sources 104
  • 9.4 Research Methodology 105
    • 9.4.1 Coverage 105
    • 9.4.2 Secondary Research 105
    • 9.4.3 Primary Research 106
  • 9.5 Therapeutic Landscape 107
    • 9.5.1 Epidemiology-based Forecasting 107
    • 9.5.2 Market Size by Geography 109
  • 9.6 Geographical Landscape 110
  • 9.7 Pipeline Analysis 110
  • 9.8 Competitive Landscape 110
    • 9.8.1 Expert Panel Validation 110
  • 9.9 Contact Us 110
  • 9.10 Disclaimer 110

List of Tables

1.1 List of Tables

  • Table 1: Global Antidepressants Market, Marketed Products, 2012 19
  • Table 2: Antidepressants Market, Global, Revenue ($bn), 2004-2011 21
  • Table 3: Antidepressants Market, Global, Revenue Forecast ($bn), 2011-2018 22
  • Table 4: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004-2011 23
  • Table 5: Antidepressants Market, Global, Annual Cost of Therapy ($), 2011-2018 23
  • Table 6: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2004-2011 24
  • Table 7: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2011-2018 24
  • Table 8: Antidepressants Market, MDD, Global, Revenue ($bn), 2004-2011 30
  • Table 9: Antidepressants Market, MDD, Global, Revenue Forecast ($bn), 2011-2018 30
  • Table 10: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004-2011 31
  • Table 11: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2011-2018 31
  • Table 12: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004-2011 32
  • Table 13: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2011-2018 32
  • Table 14: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004-2011 34
  • Table 15: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2011-2018 34
  • Table 16: Common Obsessions and Compulsions in Obsessive-Compulsive Disorder 38
  • Table 17: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004-2011 39
  • Table 18: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue Forecast ($bn), 2011-2018 39
  • Table 19: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004-2011 40
  • Table 20: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2011-2018 40
  • Table 21: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004-2011 41
  • Table 22: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2011-2018 41
  • Table 23: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004-2011 43
  • Table 24: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2011-2018 43
  • Table 25: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004-2011 47
  • Table 26: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue Forecast ($bn), 2011-2018 47
  • Table 27: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004-2011 48
  • Table 28: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2011-2018 48
  • Table 29: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004-2011 50
  • Table 30: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2011-2018 50
  • Table 31: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004-2011 53
  • Table 32: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2011-2018 53
  • Table 33: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004-2011 58
  • Table 34: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2011-2018 58
  • Table 35: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004-2011 59
  • Table 36: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2011-2018 59
  • Table 37: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004-2011 60
  • Table 38: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2011-2018 61
  • Table 39: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004-2011 63
  • Table 40: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2011-2018 63
  • Table 41: Antidepressants Market, Global, Revenues by Geography ($bn), 2004-2011 66
  • Table 42: Antidepressants Market, Global, Revenues by Geography ($bn), 2011-2018 67
  • Table 43: Antidepressants Market, The US, Revenue ($bn), 2004-2011 68
  • Table 44: Antidepressants Market, The US, Revenue Forecast ($bn), 2011-2018 68
  • Table 45: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004-2011 69
  • Table 46: Antidepressants Market, The US, Annual Cost of Therapy ($), 2011-2018 69
  • Table 47: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004-2011 70
  • Table 48: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2011-2018 70
  • Table 49: Antidepressants Market, EU5, Revenue ($bn), 2004-2011 72
  • Table 50: Antidepressants Market, EU5, Revenue Forecast ($bn), 2011-2018 72
  • Table 51: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004-2011 73
  • Table 52: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2011-2018 73
  • Table 53: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004-2011 74
  • Table 54: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2011-2018 74
  • Table 55: Antidepressants Market, Japan, Revenue ($m), 2004-2011 76
  • Table 56: Antidepressants Market, Japan, Revenue ($m), 2011-2018 76
  • Table 57: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004-2011 77
  • Table 58: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2011-2018 77
  • Table 59: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004-2011 78
  • Table 60: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2011-2018 78
  • Table 61: Antidepressants Market, Pipeline, 2012 79
  • Table 62: Lundbeck, Antidepressant Pipeline Products, 2011 87
  • Table 63: AstraZeneca, Antidepressants Pipeline, 2011 89
  • Table 64: Eli Lilly and Company, Antidepressants Pipeline, 2011 90
  • Table 65: Forest Laboratories, MDD, Pipeline Products, 2011 91

List of Figures

1.2 List of Figures

  • Figure 1: Antidepressants Market, Global, Revenue ($bn), 2004-2018 21
  • Figure 2: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004-2018 23
  • Figure 3: Antidepressants Market, Global, Therapeutic Usage Patterns (millions), 2004-2018 24
  • Figure 4: Antidepressants Market, MDD, Global, Revenue ($bn), 2004-2018 30
  • Figure 5: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004-2018 31
  • Figure 6: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004-2018 32
  • Figure 7: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004-2018 34
  • Figure 8: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004-2018 39
  • Figure 9: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004-2018 40
  • Figure 10: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004-2018 41
  • Figure 11: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004-2018 43
  • Figure 12: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004-2018 47
  • Figure 13: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004-2018 48
  • Figure 14: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004-2018 50
  • Figure 15: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004-2018 52
  • Figure 16: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004-2018 58
  • Figure 17: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004-2018 59
  • Figure 18: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004-2018 60
  • Figure 19: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004-2018 63
  • Figure 20: Antidepressants Market, Global, Revenues by Geography ($bn), 2004-2018 66
  • Figure 21: Antidepressants Market, The US, Revenue ($bn), 2004-2018 68
  • Figure 22: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004-2018 69
  • Figure 23: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004-2018 70
  • Figure 24: Antidepressants Market, EU5, Revenue ($bn), 2004-2018 72
  • Figure 25: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004-2018 73
  • Figure 26: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004-2018 74
  • Figure 27: Antidepressants Market, Japan, Revenue ($m), 2004-2018 75
  • Figure 28: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004-2018 76
  • Figure 29: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004-2018 77
  • Figure 30: Antidepressants Market, SWOT Analysis, Lundbeck, 2011 88
  • Figure 31: Antidepressants Market, SWOT Analysis, AstraZeneca, 2011 89
  • Figure 32: Antidepressants Market, SWOT Analysis, Eli Lilly and Company, 2011 90
  • Figure 33: Antidepressants Market, SWOT Analysis, Forest Laboratories, 2011 91
  • Figure 34: Antidepressants Market, SWOT Analysis, Pfizer Inc., 2011 93
  • Figure 35: Antidepressants Market, SWOT Analysis, GlaxoSmithKline, 2011 94
  • Figure 36: Antidepressants Market, SWOT Analysis, Bristol-Myers Squibb, 2011 95
  • Figure 37: GBI Research Market Forecasting Model 109

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives published by GBI Research in October 15, 2012. This report consists of Pages: 110 and the price starts from US $ 3500.

Back to Top